je.st
news
Merck Statement on FDA Advisory Committee Meeting for Suvorexant
2013-05-23 00:28:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today provided the following statement after the conclusion of the Peripheral and Central Nervous System Drugs Advisory Committee meeting of the U.S. Food and Drug Administration (FDA) about suvorexant, Mercks investigational medicine to treat insomnia. Language: English Contact HTML: MerckMedia:Pam Eisele, 908-423-5042orTracy Ogden, 267-305-2301orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: statement
meeting
committee
advisory
Category:Biotechnology and Pharmaceuticals